论文部分内容阅读
目的探讨尿激酶溶栓治疗急性心肌梗死(AMI)的临床疗效。方法对66例急性心肌梗死患者于发病12 h以内给予尿激酶(天津生物化学制药有限公司生产,国药准字:H12020492)150万U+生理盐水100 ml,30 min内静脉滴入。结果本组入选66例患者中,溶栓成功者53例,成功率为80.3%;溶栓未通者13例。溶栓成功者于2 h内心电图抬高的ST段均回落>50%;胸痛明显缓解或者基本消失;血清肌酸磷酸激酶同工酶(CK-MB)的峰值出现前移,于14 h内提前出现;患者于2 h内出现再灌注性心律失常(以室性心律失常常见)。结论用尿激酶溶栓治疗急性心肌梗死,闭塞血管再通率高,临床效果好,在基层医院尤其适用。
Objective To investigate the clinical efficacy of urokinase thrombolysis in the treatment of acute myocardial infarction (AMI). Methods Sixty-six patients with acute myocardial infarction were treated with intravenous infusion of urokinase (produced by Tianjin Biochemical Pharmaceutical Co., Ltd., Zhunzi H12020492) with 1.5 million U + normal saline within 12 hours after the onset of acute myocardial infarction. Results The group of 66 patients enrolled in the successful thrombolysis in 53 cases, the success rate was 80.3%; thrombolysis failed in 13 cases. Thrombolytic successful in 2 h ECG elevation ST segment were more than 50%; chest pain was relieved or disappeared; peak serum creatine phosphokinase (CK-MB) peak forward within 14 h Premature emergence; patients within 2 h reperfusion arrhythmias (ventricular arrhythmias common). Conclusion Urokinase thrombolytic therapy of acute myocardial infarction, occlusion of vascular recanalization rate, clinical effect is good, especially in the primary hospital.